What did @aubreysikeee actually say?
The creator shared a week-five update on their semaglutide journey, announcing a move from 0.25 mg to 0.5 mg after four weeks. They reported losing eight pounds in that time. They also described the injection process in detail, including counting "36 clicks" to dial up the new dose, using third-party needles purchased from Amazon, and squeezing fat tissue before injecting. A link to a virtual prescriber was mentioned in the bio.
This is a sponsored post, tagged #minutemdpartner, which means it is advertising a telehealth service. That context matters when evaluating how the dosing guidance is framed and who it might influence.
Does the science back this up?
The dose escalation schedule is roughly consistent with clinical guidelines, but the injection method description contains real errors that could affect both safety and efficacy. The weight loss reported is plausible but on the higher end of what trials show at this stage.
The standard titration protocol for semaglutide, as used in the STEP trials (Wilding et al., 2021, New England Journal of Medicine), starts at 0.25 mg for four weeks as a tolerability dose before moving to 0.5 mg. That part matches. However, those trials used the Ozempic auto-injector with fixed dose settings, not a compounded product dialed by click count. Counting clicks to approximate a dose is not a validated delivery method for any approved semaglutide product and introduces real risk of dosing error.
Eight pounds in four weeks is above the average seen in clinical trials at 0.25 mg, where weight loss in the early weeks is typically modest, partly because 0.25 mg is not considered a therapeutic weight-loss dose but a ramp-up dose. Individual variation is real, but viewers should not expect to replicate this result.
What did they get wrong (or right)?
The click-counting method is the most significant problem here. The creator says they used "18 clicks" for 0.25 mg and will now do "36 clicks" to double the dose to 0.5 mg. This implies a compounded semaglutide product delivered via a vial-and-syringe or custom pen system, not an FDA-approved Ozempic or Wegovy device. Compounded semaglutide is not FDA-approved, and the FDA has issued warnings about dosing errors with compounded versions, particularly those using vials where users self-calculate doses (FDA Safety Communication, 2024).
Using needles purchased from Amazon rather than those supplied or verified by the dispensing pharmacy adds another layer of concern. Needle gauge and length affect injection depth, which affects absorption. This is not a minor detail.
What they got right: the general timeline of four weeks at 0.25 mg before escalating is consistent with standard prescribing guidance. Injecting into subcutaneous fat tissue, as they describe, is also correct technique. Holding the injection in place briefly before withdrawing is appropriate.
What should you actually know?
If you are considering semaglutide through a telehealth platform, the dosing method matters as much as the dose itself. The click-counting approach shown here is not a reliable way to measure a GLP-1 dose. A 2024 FDA alert specifically called out compounded semaglutide products for dosing confusion, including cases where patients received ten times the intended dose.
Weight loss at week four on a 0.25 mg ramp-up dose varies considerably. The STEP 1 trial showed an average of about 14.9 percent body weight loss over 68 weeks at the full 2.4 mg dose, not in the first month. Anyone expecting eight-pound losses every four weeks through the entire course is likely to be disappointed.
A licensed telehealth provider should be explaining your specific injection device and how to use it accurately, not leaving patients to figure out click counts or source their own needles. If yours is not doing that, it is a reasonable question to raise.